Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood Cancer Discovery|June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestryKylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Nature Communications|August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell levelLukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood Cancer Discovery|June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestryKylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Nature Communications|August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell levelLukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 18